-
3 days ago | 
thecardiologyadvisor.com | natasha persaud
Finerenone treatment reduces cardiovascular and kidney risks in patients with chronic kidney disease (CKD) and type 2 diabetes, regardless of their baseline anemia status, a new study finds. In a prespecified post hoc analysis, investigators pooled data from 12,971 patients with diabetic kidney disease (DKD) from the FIDELIO-DKD and FIGARO-DKD randomized controlled trials.
-
4 days ago | 
renalandurologynews.com | natasha persaud
Childhood cancer survivors develop hypertension and chronic kidney disease (CKD) at a higher rate than other pediatric populations, sick or well, a recent study finds. Asaf Lebel, MD, of Ha’Emek Medical Center in Afula, Israel, and colleagues investigated the onset of hypertension or CKD up to 27 years after childhood cancer treatment using administrative health care data from Ontario, Canada. The Ontario population is ethnically diverse and has universal health care.
-
5 days ago | 
renalandurologynews.com | natasha persaud
A prospective observational study of transgender individuals receiving sex hormones opens a window into kidney physiology.
-
5 days ago | 
renalandurologynews.com | natasha persaud
Zilebesiran added to hypertension background therapy further reduces systolic blood pressure (SBP) within 3 months, investigators report. Zilebesiran is an investigational RNA interference therapeutic that reduces angiotensinogen production.
-
5 days ago | 
rheumatologyadvisor.com | natasha persaud
It is well known that systemic lupus erythematosus (SLE) increases the risks for both pregnancy complications and cardiovascular events. Now a new study finds that women with SLE who experience cardiovascular events during pregnancy have higher risks of adverse maternal and infant outcomes, particularly when they have lupus nephritis or antiphospholipid antibodies (APS).
-
1 week ago | 
renalandurologynews.com | natasha persaud
Voclosporin treatment can further reduce the urinary protein to creatinine ratio (UPCR) to less than 0.5 g/g in a subset of patients with lupus nephritis, investigators reported at LUPUS 2025, the 16th international congress on systemic lupus erythematosus (SLE). Although the UPCR efficacy target is less than 0.5 g/g in many trials, the disease may still be active at this threshold.
-
1 week ago | 
rheumatologyadvisor.com | natasha persaud
Lupus nephritis frequently recurs after kidney transplantation, and it may be clinically quiescent, investigators report. Among 112 first-time kidney transplant recipients with lupus nephritis history, 40 (35.7%) experienced lupus nephritis recurrence in the graft, Maria Lourdes Gonzalez Suarez, MD, PhD, of Mayo Clinic in Rochester, Minnesota, and colleagues reported in Kidney International Reports.
-
1 week ago | 
renalandurologynews.com | natasha persaud
Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobin targets, is associated with increased risk for major adverse cardiovascular events (MACE), investigators confirm.
-
2 weeks ago | 
rheumatologyadvisor.com | natasha persaud
In patients with active lupus nephritis, at least 3 years of sustained clinical remission is necessary to prevent kidney damage and onset of stage 3 or higher chronic kidney disease (CKD), a new study finds. Sustained clinical remission was defined as an estimated glomerular filtration rate (eGFR) of more than 60 mL/min/1.73 m2, proteinuria of less than 0.5 g/24h, and a clinical systemic lupus erythematosus (SLE) disease activity index of 0 for at least 1 year.
-
2 weeks ago | 
renalandurologynews.com | natasha persaud
Among US trial participants with anemia of chronic kidney disease (CKD), vadadustat and darbepoetin alfa show similar efficacy and risk for major adverse cardiovascular events (MACE) in both the dialysis-dependent (DD) and non-dialysis dependent (NDD) groups, investigators report. This finding differs somewhat from global trial results where vadadustat did not meet noninferiority criteria for cardiovascular safety among patients with NDD-CKD.
